share_log

Immutep Reports Initial Safety Data For IMP761, The First LAG-3 Agonist, In Phase I Trial With No Treatment-Related Adverse Events; Additional Data Expected In H1 2025 To Support Autoimmune Disease Treatment Potential

Benzinga ·  Dec 17, 2024 21:23
Immutep Reports Initial Safety Data For IMP761, The First LAG-3 Agonist, In Phase I Trial With No Treatment-Related Adverse Events; Additional Data Expected In H1 2025 To Support Autoimmune Disease Treatment Potential
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment